$VINC
Vincerx Pharma, Inc.

2022 Q3 Form 10-Q Financial Statement

#000119312522218561 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.525M $4.722M $5.656M
YoY Change -20.89% -29.47% 18.08%
% of Gross Profit
Research & Development $11.07M $13.74M $15.97M
YoY Change -9.38% 28.45% 230.39%
% of Gross Profit
Depreciation & Amortization $13.00K $13.00K $14.00K
YoY Change
% of Gross Profit
Operating Expenses $16.90M $19.62M $21.63M
YoY Change -5.74% 12.82% 124.7%
Operating Profit -$16.90M -$19.62M -$21.63M
YoY Change -5.74% 12.82% 124.7%
Interest Expense $125.0K $1.202M $5.211M
YoY Change -101.89% -92.17% 55.55%
% of Operating Profit
Other Income/Expense, Net $22.00K $1.202M -$8.000K
YoY Change 69.23% -92.17%
Pretax Income -$16.88M -$18.42M -$16.42M
YoY Change -31.17% 805.65% 161.53%
Income Tax
% Of Pretax Income
Net Earnings -$16.88M -$18.42M -$16.42M
YoY Change -31.17% 805.65% 161.7%
Net Earnings / Revenue
Basic Earnings Per Share -$0.80 -$0.88 -$0.79
Diluted Earnings Per Share -$0.80 -$0.88 -$786.0K
COMMON SHARES
Basic Shares Outstanding 21.19M 21.00K 20.90K
Diluted Shares Outstanding 21.08K 21.00K 20.90K

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $65.97M $80.86M $96.49M
YoY Change -46.27% -5.57% 80.82%
Cash & Equivalents $45.80M $80.92M $96.49M
Short-Term Investments $20.17M
Other Short-Term Assets $746.0K $619.0K $1.578M
YoY Change 65.04% -29.82% 50.29%
Inventory
Prepaid Expenses $470.0K $847.0K
Receivables
Other Receivables
Total Short-Term Assets $67.26M $82.39M $98.06M
YoY Change -45.43% -4.76% 80.24%
LONG-TERM ASSETS
Property, Plant & Equipment $188.0K $202.0K $3.950M
YoY Change -95.75% -95.46% 17.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.642M $1.642M $1.867M
YoY Change -6.6% 778.07% 748.64%
Total Long-Term Assets $5.121M $5.358M $5.817M
YoY Change -17.1% 15.67% 61.94%
TOTAL ASSETS
Total Short-Term Assets $67.26M $82.39M $98.06M
Total Long-Term Assets $5.121M $5.358M $5.817M
Total Assets $72.38M $87.74M $103.9M
YoY Change -44.08% -3.72% 79.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.393M $5.118M $3.386M
YoY Change 94.47% 179.67% 634.49%
Accrued Expenses $4.445M $4.331M $852.0K
YoY Change 735.53% 1103.06% -38.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.950M $10.45M $11.53M
YoY Change -60.46% -33.37% -60.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $50.00K $2.930M $3.186M
YoY Change -98.63% -24.05% -2.87%
Total Long-Term Liabilities $50.00K $2.930M $3.186M
YoY Change -98.63% -24.05% -2.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.950M $10.45M $11.53M
Total Long-Term Liabilities $50.00K $2.930M $3.186M
Total Liabilities $12.67M $13.38M $14.71M
YoY Change -56.01% -31.53% -54.66%
SHAREHOLDERS EQUITY
Retained Earnings -$107.7M -$90.82M
YoY Change
Common Stock $2.000K $2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $59.71M $74.36M $89.17M
YoY Change
Total Liabilities & Shareholders Equity $72.38M $87.74M $103.9M
YoY Change -44.08% -3.72% 79.11%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$16.88M -$18.42M -$16.42M
YoY Change -31.17% 805.65% 161.7%
Depreciation, Depletion And Amortization $13.00K $13.00K $14.00K
YoY Change
Cash From Operating Activities -$14.87M -$15.89M -$15.03M
YoY Change 44.33% 94.41% 337.24%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$20.20M $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$20.20M $0.00 $0.00
YoY Change 91695.45% -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 242.0K 0.000
YoY Change -100.0% -99.4%
NET CHANGE
Cash From Operating Activities -14.87M -15.89M -15.03M
Cash From Investing Activities -20.20M 0.000 0.000
Cash From Financing Activities 0.000 242.0K 0.000
Net Change In Cash -35.07M -15.64M -15.03M
YoY Change -194.33% -148.48% 78.12%
FREE CASH FLOW
Cash From Operating Activities -$14.87M -$15.89M -$15.03M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$14.87M -$15.89M
YoY Change 44.64% 99.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001796129
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
13742000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10698000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
29713000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39244
dei Entity Registrant Name
EntityRegistrantName
Vincerx Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-3197402
dei Entity Address Address Line1
EntityAddressAddressLine1
260 Sheridan Avenue, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94306
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
800-6676
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
VINC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21189769
CY2022Q2 us-gaap Cash
Cash
80857000
CY2021Q4 us-gaap Cash
Cash
111459000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
63000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
105000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
847000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
182000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
619000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
95000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
82386000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
111841000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3514000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3949000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
202000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
233000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1642000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1653000
CY2022Q2 us-gaap Assets
Assets
87744000
CY2021Q4 us-gaap Assets
Assets
117676000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5118000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2019000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4331000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4715000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
968000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
738000
CY2022Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
34000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6447000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10451000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13919000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2930000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3436000
CY2022Q2 us-gaap Liabilities
Liabilities
13381000
CY2021Q4 us-gaap Liabilities
Liabilities
17355000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21189769
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21189769
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21057560
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21057560
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
165173000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
156311000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90816000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55971000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
74363000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
100321000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87744000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117676000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4722000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6695000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10378000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11486000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15532000
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
1159000
us-gaap Restructuring Charges
RestructuringCharges
1159000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
19623000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
17393000
us-gaap Operating Expenses
OperatingExpenses
41250000
us-gaap Operating Expenses
OperatingExpenses
27018000
us-gaap Share Based Compensation
ShareBasedCompensation
8620000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25000
us-gaap Net Income Loss
NetIncomeLoss
-34845000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
74363000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
25553000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19623000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17393000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41250000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27018000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1202000
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-15359000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6413000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-18708000
us-gaap Interest Expense
InterestExpense
8000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1202000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15359000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6405000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18708000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18421000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2034000
us-gaap Net Income Loss
NetIncomeLoss
-34845000
us-gaap Net Income Loss
NetIncomeLoss
-8310000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
10000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18411000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2034000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34820000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8310000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20995
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20995
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16350
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16350
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20946
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20946
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15050
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15050
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
89170000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
242000
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3362000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
10000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18421000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
74363000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
100321000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
242000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40671000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
768000
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
6637000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2034000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
71595000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
25379000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40671000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2503000
us-gaap Share Based Compensation
ShareBasedCompensation
11352000
us-gaap Net Income Loss
NetIncomeLoss
-8310000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
71595000
us-gaap Profit Loss
ProfitLoss
-34845000
us-gaap Profit Loss
ProfitLoss
-8310000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
8620000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
11352000
vinc Amortization Of Right Of Use Assets Liabilities
AmortizationOfRightOfUseAssetsLiabilities
435000
vinc Amortization Of Right Of Use Assets Liabilities
AmortizationOfRightOfUseAssetsLiabilities
-51000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6413000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-18708000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1189000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-436000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-11000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
105000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3099000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1339000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-384000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2397000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-14000
vinc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-276000
vinc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
52000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30915000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11612000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5000000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
0
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
228000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5228000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
242000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
40671000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
242000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40671000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30644000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23831000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111564000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61792000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80920000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85623000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
25000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2503000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4166000
us-gaap Nature Of Operations
NatureOfOperations
<div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">NOTE 1. NATURE OF BUSINESS </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSAC was initially formed on December 19, 2018 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. In December 2020, the Merger Sub merged with and into Legacy Vincera Pharma, with Legacy Vincera Pharma surviving the Merger as a wholly- owned subsidiary of LSAC. In connection with the Business Combination, LSAC changed its name to Vincera Pharma, Inc., and subsequently in January 2021, changed its name to Vincerx Pharma, Inc. (together with its consolidated subsidiaries, the “Company”). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The Company’s current pipeline is entirely derived from the Bayer License Agreement (see Note 3), pursuant to which the Company has been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> small molecule drug program and a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and small molecule drug conjugates. The Company intends to use these product candidates to treat various cancers in a patient-specific, targeted approach. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the early months of 2020, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> emerged and subsequently spread world-wide. The World Health Organization declared <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> a pandemic resulting in federal, state and local governments and private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders, and advisories, quarantining people who may have been exposed to the virus and other measures. Our business operations, and those of third parties with whom we conduct business, have been, and could continue to be, adversely affected by the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. The extent to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could continue to impact our business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as duration of the pandemic, the emergence and severity of new variants of the virus, additional or modified government actions, new information concerning the severity and impact of the virus, the timing, availability, efficacy, adoption and distribution of vaccines or other preventative treatments, travel restrictions, quarantines, social distancing requirements and business closures and other actions taken to contain the virus or address its impact. Management continues to evaluate the impact of the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its current operations and future plans and intends to take appropriate measures to address any such impact, but there can be no assurance that these efforts will be successful and that the pandemic will not continue to have <div style="display:inline;">a </div>negative effect on the Company’s financial position and results of its operations. </div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-12-19
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, those related to our accrued clinical trial and manufacturing expenses, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </div>
vinc Date Of Licence Agreement
DateOfLicenceAgreement
2020-10-07
CY2021Q1 vinc Licence Fee Paid
LicenceFeePaid
5000000
CY2022Q2 vinc Aggregate Milestone Payments Payable
AggregateMilestonePaymentsPayable
1000000000
CY2022Q2 vinc Percentage Of Employees Reduction
PercentageOfEmployeesReduction
0.33
CY2022Q2 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
2500000
CY2022Q2 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
1200000
CY2020Q4 vinc Date Of Lease Agreement
DateOfLeaseAgreement
P5Y
CY2020Q4 vinc Date Of Lease Commencement
DateOfLeaseCommencement
2021-01-01
CY2020Q4 us-gaap Lease Cost
LeaseCost
1100000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3900000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7238000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6467000
us-gaap Operating Lease Cost
OperatingLeaseCost
598000
us-gaap Operating Lease Cost
OperatingLeaseCost
83000
us-gaap Variable Lease Cost
VariableLeaseCost
0
us-gaap Variable Lease Cost
VariableLeaseCost
0
us-gaap Lease Cost
LeaseCost
598000
us-gaap Lease Cost
LeaseCost
83000
us-gaap Operating Lease Payments
OperatingLeasePayments
438000
us-gaap Operating Lease Payments
OperatingLeasePayments
70000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4166000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2022Q2 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
608000
CY2022Q2 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1261000
CY2022Q2 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
1284000
CY2022Q2 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
1336000
CY2022Q2 us-gaap Contractual Obligation
ContractualObligation
4489000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
591000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3898000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21189769
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21057560
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3408
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.74
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1166
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
631
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.58
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3943
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.37
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1916
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
18.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9.5
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
5.62
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
19.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.836
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.755
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3362000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6637000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8620000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11352000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18421000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2034000
us-gaap Net Income Loss
NetIncomeLoss
-34845000
us-gaap Net Income Loss
NetIncomeLoss
-8310000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20995
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20995
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16350
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16350
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20946
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20946
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15050
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15050
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55

Files In Submission

Name View Source Status
0001193125-22-218561-index-headers.html Edgar Link pending
0001193125-22-218561-index.html Edgar Link pending
0001193125-22-218561.txt Edgar Link pending
0001193125-22-218561-xbrl.zip Edgar Link pending
d737309d10q.htm Edgar Link pending
d737309dex311.htm Edgar Link pending
d737309dex312.htm Edgar Link pending
d737309dex321.htm Edgar Link pending
d737309dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vinc-20220630.xsd Edgar Link pending
vinc-20220630_def.xml Edgar Link unprocessable
vinc-20220630_pre.xml Edgar Link unprocessable
vinc-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
vinc-20220630_cal.xml Edgar Link unprocessable
d737309d10q_htm.xml Edgar Link completed